O	O	0	15	Transcriptional	Transcriptional	B-NP	JJ	O	2	NMOD	O
O	O	16	24	analysis	analysis	I-NP	NN	O	19	NMOD	O
O	O	25	27	of	of	B-PP	IN	O	2	NMOD	O
T8	B-Entity	28	35	Epstein	Epstein	B-NP	NNP	O	9	NMOD	O
T8	I-Entity	35	36	-	-	I-NP	HYPH	O	9	NMOD	O
T8	I-Entity	36	40	Barr	Barr	I-NP	NNP	O	9	NMOD	O
T8	I-Entity	41	46	virus	virus	I-NP	NN	O	9	NMOD	O
T8	I-Entity	47	51	gene	gene	I-NP	NN	O	9	NMOD	O
O	O	52	62	expression	expression	I-NP	NN	O	3	PMOD	O
O	O	63	65	in	in	B-PP	IN	O	9	NMOD	O
O	O	66	69	EBV	EBV	B-NP	NN	O	15	NMOD	O
O	O	69	70	-	-	B-NP	HYPH	O	15	NMOD	O
O	O	70	78	positive	positive	I-NP	JJ	O	15	NMOD	O
O	O	79	86	gastric	gastric	I-NP	JJ	O	15	NMOD	O
O	O	87	96	carcinoma	carcinoma	I-NP	NN	O	10	PMOD	O
O	O	96	97	:	:	O	:	O	2	P	O
O	O	98	104	unique	unique	B-NP	JJ	O	19	NMOD	O
O	O	105	110	viral	viral	I-NP	JJ	O	19	NMOD	O
O	O	111	118	latency	latency	I-NP	NN	O	0	ROOT	O
O	O	119	121	in	in	B-PP	IN	O	19	NMOD	O
O	O	122	125	the	the	B-NP	DT	O	23	NMOD	O
O	O	126	132	tumour	tumour	I-NP	NN	B-cell_type	23	NMOD	B-cell_type
O	O	133	138	cells	cell	I-NP	NNS	I-cell_type	20	PMOD	I-cell_type
O	O	138	139	.	.	O	.	O	19	P	O

O	O	141	149	Although	Although	B-SBAR	IN	O	36	VMOD	O
O	O	150	154	case	case	O	NN	O	20	VMOD	O
O	O	154	155	-	-	O	HYPH	O	20	P	O
O	O	155	163	oriented	orient	B-NP	VBN	O	5	NMOD	O
O	O	164	172	evidence	evidence	I-NP	NN	O	20	SUB	O
O	O	173	176	for	for	B-PP	IN	O	5	NMOD	O
O	O	177	179	an	an	B-NP	DT	O	8	NMOD	O
O	O	180	191	association	association	I-NP	NN	O	6	PMOD	O
O	O	192	194	of	of	B-PP	IN	O	8	NMOD	O
O	O	195	202	Epstein	Epstein	B-NP	NNP	O	9	PMOD	O
O	O	202	203	-	-	I-NP	HYPH	O	10	NMOD	O
O	O	203	207	Barr	Barr	I-NP	NNP	O	13	NMOD	O
O	O	208	213	virus	virus	I-NP	NN	O	11	OBJ	O
O	O	214	215	(	(	O	(	O	16	DEP	O
O	O	215	218	EBV	EBV	B-NP	NN	O	16	DEP	O
O	O	218	219	)	)	O	)	O	13	NMOD	O
O	O	220	224	with	with	B-PP	IN	O	13	NMOD	O
O	O	225	232	gastric	gastric	B-NP	JJ	O	19	NMOD	O
O	O	233	242	carcinoma	carcinoma	I-NP	NN	O	17	PMOD	O
O	O	243	246	has	have	B-VP	VBZ	O	1	SBAR	O
O	O	247	251	been	be	I-VP	VBN	O	20	VC	O
O	O	252	264	accumulating	accumulate	I-VP	VBG	O	21	VC	O
O	O	265	273	recently	recently	B-ADVP	RB	O	22	VMOD	O
O	O	273	274	,	,	O	,	O	36	P	O
O	O	275	278	the	the	B-NP	DT	O	28	NMOD	O
O	O	279	290	interaction	interaction	I-NP	NN	O	28	NMOD	O
O	O	290	291	(	(	I-NP	(	O	28	NMOD	O
O	O	291	292	s	s	I-NP	NNS	O	36	SUB	O
O	O	292	293	)	)	O	)	O	28	NMOD	O
O	O	294	301	between	between	B-PP	IN	O	28	NMOD	O
O	O	302	305	EBV	EBV	B-NP	NN	O	35	NMOD	O
O	O	306	309	and	and	O	CC	O	35	NMOD	O
O	O	310	317	gastric	gastric	B-NP	JJ	B-cell_type	35	NMOD	B-cell_type
O	O	318	328	epithelial	epithelial	I-NP	JJ	I-cell_type	35	NMOD	I-cell_type
O	O	329	334	cells	cell	I-NP	NNS	I-cell_type	30	PMOD	I-cell_type
O	O	335	337	is	be	B-VP	VBZ	O	38	VMOD	O
O	O	337	338	/	/	B-NP	SYM	O	38	P	O
O	O	338	341	are	be	B-VP	VBP	O	0	ROOT	O
O	O	342	349	largely	largely	B-ADJP	RB	O	40	AMOD	O
O	O	350	357	unknown	unknown	I-ADJP	JJ	O	38	PRD	O
O	O	357	358	.	.	O	.	O	38	P	O

O	O	359	361	In	In	B-PP	IN	O	6	VMOD	O
O	O	362	366	this	this	B-NP	DT	O	3	NMOD	O
O	O	367	372	study	study	I-NP	NN	O	1	PMOD	O
O	O	372	373	,	,	O	,	O	6	P	O
O	O	374	376	we	we	B-NP	PRP	O	6	SUB	O
O	O	377	385	examined	examine	B-VP	VBD	O	0	ROOT	O
O	O	386	391	seven	seven	B-NP	CD	O	13	NMOD	O
O	O	392	395	EBV	EBV	I-NP	NN	O	13	NMOD	O
O	O	395	396	-	-	B-NP	HYPH	O	13	NMOD	O
O	O	396	404	positive	positive	I-NP	JJ	O	13	NMOD	O
O	O	405	412	gastric	gastric	I-NP	JJ	O	13	NMOD	O
O	O	413	422	carcinoma	carcinoma	I-NP	NN	O	13	NMOD	O
O	O	423	430	tissues	tissue	I-NP	NNS	O	6	OBJ	O
O	O	431	434	for	for	B-PP	IN	O	13	NMOD	O
O	O	435	440	viral	viral	B-NP	JJ	O	17	NMOD	O
O	O	441	445	gene	gene	I-NP	NN	O	17	NMOD	O
O	O	446	456	expression	expression	I-NP	NN	O	14	PMOD	O
O	O	457	459	at	at	B-PP	IN	O	13	NMOD	O
O	O	460	463	the	the	B-NP	DT	O	21	NMOD	O
O	O	464	468	mRNA	mRNA	I-NP	NN	B-RNA	21	NMOD	B-RNA
O	O	469	474	level	level	I-NP	NN	O	18	PMOD	O
O	O	474	475	,	,	O	,	O	13	P	O
O	O	476	480	from	from	B-PP	IN	O	13	NMOD	O
O	O	481	486	which	which	B-NP	WDT	O	23	PMOD	O
O	O	487	494	studies	study	B-NP	NNS	O	23	PMOD	O
O	O	495	497	on	on	B-PP	IN	O	6	VMOD	O
O	O	498	501	the	the	B-NP	DT	O	29	NMOD	O
O	O	502	505	EBV	EBV	I-NP	NN	O	29	NMOD	O
O	O	506	518	oncogenicity	oncogenicity	I-NP	NN	O	26	PMOD	O
O	O	519	521	in	in	B-PP	IN	O	29	NMOD	O
O	O	522	527	human	human	B-NP	JJ	B-cell_type	33	NMOD	B-cell_type
O	O	528	538	epithelial	epithelial	I-NP	JJ	I-cell_type	33	NMOD	I-cell_type
O	O	539	544	cells	cell	I-NP	NNS	I-cell_type	30	PMOD	I-cell_type
O	O	545	549	will	will	B-VP	MD	O	6	VMOD	O
O	O	550	557	benefit	benefit	I-VP	VB	O	34	VC	O
O	O	557	558	.	.	O	.	O	6	P	O

O	O	559	566	Reverse	Reverse	B-NP	JJ	O	2	NMOD	O
O	O	567	580	transcription	transcription	I-NP	NN	O	5	NMOD	O
O	O	580	581	-	-	O	HYPH	O	5	NMOD	O
O	O	581	584	PCR	PCR	B-NP	NN	O	5	NMOD	O
O	O	585	593	analysis	analysis	I-NP	NN	O	6	SUB	O
O	O	594	600	showed	show	B-VP	VBD	O	0	ROOT	O
O	O	601	605	that	that	B-SBAR	IN	O	6	VMOD	O
O	O	606	609	all	all	B-NP	DT	O	14	NMOD	O
O	O	610	615	seven	seven	I-NP	CD	O	14	NMOD	O
O	O	616	619	EBV	EBV	I-NP	NN	O	14	NMOD	O
O	O	619	620	-	-	I-NP	HYPH	O	14	NMOD	O
O	O	620	628	positive	positive	I-NP	JJ	O	14	NMOD	O
O	O	629	635	tumour	tumour	I-NP	NN	O	14	NMOD	O
O	O	636	643	tissues	tissue	I-NP	NNS	O	16	SUB	O
O	O	644	658	constitutively	constitutively	B-ADVP	RB	O	16	VMOD	O
O	O	659	668	expressed	express	B-VP	VBD	O	7	SBAR	O
T1	B-Protein	669	672	EBV	EBV	B-NP	NN	B-RNA	19	NMOD	B-RNA
T1	I-Protein	673	680	nuclear	nuclear	I-NP	JJ	I-RNA	19	NMOD	I-RNA
T1	I-Protein	681	688	antigen	antigen	I-NP	NN	I-RNA	24	NMOD	I-RNA
T1	I-Protein	689	690	(	(	O	(	I-RNA	22	DEP	I-RNA
T1	I-Protein	690	694	EBNA	EBNA	B-NP	NN	I-RNA	22	DEP	I-RNA
T1	I-Protein	694	695	)	)	O	)	I-RNA	19	NMOD	I-RNA
T1	I-Protein	696	697	1	1	B-NP	CD	I-RNA	24	NMOD	I-RNA
O	O	698	702	mRNA	mRNA	I-NP	NN	I-RNA	29	NMOD	I-RNA
O	O	702	703	,	,	B-NP	,	O	29	P	O
O	O	704	707	but	but	I-NP	CC	O	29	NMOD	O
O	O	708	711	not	not	I-NP	RB	O	26	DEP	O
T2	B-Protein	712	717	EBNA2	EBNA2	B-VP	NN	B-RNA	29	NMOD	B-RNA
O	O	718	722	mRNA	mRNA	B-NP	NN	I-RNA	16	OBJ	I-RNA
O	O	722	723	.	.	O	.	O	6	P	O

O	O	724	727	The	The	B-NP	DT	O	3	NMOD	O
O	O	728	732	EBNA	EBNA	I-NP	NN	B-protein	3	NMOD	B-protein
O	O	733	746	transcription	transcription	I-NP	NN	O	4	SUB	O
O	O	747	750	was	be	B-VP	VBD	O	22	VMOD	O
O	O	751	760	initiated	initiate	I-VP	VBN	O	4	VC	O
O	O	761	765	from	from	B-PP	IN	O	5	VMOD	O
O	O	766	769	one	one	B-NP	CD	O	13	NMOD	O
O	O	770	772	of	of	B-PP	IN	O	7	NMOD	O
O	O	773	778	three	three	B-NP	CD	O	11	NMOD	O
T9	B-Entity	779	783	EBNA	EBNA	I-NP	NN	B-DNA	11	NMOD	B-DNA
T9	I-Entity	784	793	promoters	promoter	I-NP	NNS	I-DNA	8	PMOD	I-DNA
O	O	793	794	,	,	O	,	O	13	P	O
T10	B-Entity	795	797	Qp	Qp	B-NP	NN	B-DNA	6	PMOD	B-DNA
O	O	797	798	:	:	O	:	O	4	P	O
O	O	799	801	by	by	B-PP	IN	O	4	VMOD	O
O	O	802	810	contrast	contrast	B-NP	NN	O	15	PMOD	O
O	O	810	811	,	,	O	,	O	22	P	O
O	O	812	816	both	both	O	CC	O	21	NMOD	O
T11	B-Entity	817	819	Cp	Cp	B-NP	NN	B-DNA	21	NMOD	B-DNA
O	O	820	823	and	and	O	CC	O	21	NMOD	O
T12	B-Entity	824	826	Wp	Wp	B-NP	NN	B-DNA	22	SUB	B-DNA
O	O	827	831	were	be	B-VP	VBD	O	0	ROOT	O
O	O	832	838	silent	silent	B-ADJP	JJ	O	22	PRD	O
O	O	838	839	,	,	O	,	O	22	P	O
O	O	840	844	thus	thus	B-ADVP	RB	O	26	VMOD	O
O	O	845	854	resulting	result	B-VP	VBG	O	22	VMOD	O
O	O	855	857	in	in	B-PP	IN	O	26	VMOD	O
O	O	858	861	the	the	B-NP	DT	O	29	NMOD	O
O	O	862	866	lack	lack	I-NP	NN	O	27	PMOD	O
O	O	867	869	of	of	B-PP	IN	O	29	NMOD	O
T3	B-Protein	870	875	EBNA2	EBNA2	B-NP	NN	B-RNA	32	NMOD	B-RNA
O	O	876	880	mRNA	mRNA	I-NP	NN	I-RNA	30	PMOD	I-RNA
O	O	880	881	.	.	O	.	O	22	P	O

T4	B-Protein	882	888	Latent	Latent	B-NP	JJ	B-RNA	3	NMOD	B-RNA
T4	I-Protein	889	897	membrane	membrane	I-NP	NN	I-RNA	3	NMOD	I-RNA
T4	I-Protein	898	905	protein	protein	I-NP	NN	I-RNA	8	NMOD	I-RNA
T4	I-Protein	906	907	(	(	O	(	I-RNA	6	DEP	I-RNA
T4	I-Protein	907	910	LMP	LMP	B-NP	NN	I-RNA	6	DEP	I-RNA
T4	I-Protein	910	911	)	)	O	)	I-RNA	3	NMOD	I-RNA
T4	I-Protein	912	914	2A	2A	B-NP	NN	I-RNA	8	NMOD	I-RNA
O	O	915	919	mRNA	mRNA	I-NP	NN	I-RNA	9	SUB	I-RNA
O	O	920	923	was	be	B-VP	VBD	O	24	VMOD	O
O	O	924	932	detected	detect	I-VP	VBN	O	9	VC	O
O	O	933	935	in	in	B-PP	IN	O	10	VMOD	O
O	O	936	941	three	three	B-NP	CD	O	11	PMOD	O
O	O	942	944	of	of	I-NP	IN	O	12	NMOD	O
O	O	945	950	seven	seven	I-NP	CD	O	15	NMOD	O
O	O	951	956	cases	case	I-NP	NNS	O	13	PMOD	O
O	O	956	957	;	;	O	:	O	24	P	O
O	O	958	965	however	however	B-ADVP	RB	O	24	VMOD	O
O	O	965	966	,	,	O	,	O	24	P	O
O	O	967	974	neither	neither	O	CC	O	22	NMOD	O
T5	B-Protein	975	979	LMP1	LMP1	B-NP	NN	B-protein	22	NMOD	B-protein
O	O	980	983	nor	nor	O	CC	O	22	NMOD	O
T6	B-Protein	984	989	LMP2B	LMP2B	B-NP	NN	B-RNA	23	NMOD	B-RNA
O	O	990	994	mRNA	mRNA	I-NP	NN	I-RNA	24	SUB	I-RNA
O	O	995	998	was	be	B-VP	VBD	O	0	ROOT	O
O	O	999	1007	detected	detect	I-VP	VBN	O	24	VC	O
O	O	1008	1010	in	in	B-PP	IN	O	25	VMOD	O
O	O	1011	1014	any	any	B-NP	DT	O	26	PMOD	O
O	O	1015	1017	of	of	B-PP	IN	O	27	NMOD	O
O	O	1018	1021	the	the	B-NP	DT	O	30	NMOD	O
O	O	1022	1029	tumours	tumour	I-NP	NNS	O	28	PMOD	O
O	O	1030	1036	tested	test	B-VP	VBN	O	30	NMOD	O
O	O	1036	1037	.	.	O	.	O	24	P	O

O	O	1038	1049	Transcripts	Transcript	B-NP	NNS	O	12	SUB	O
O	O	1050	1054	from	from	B-PP	IN	O	1	NMOD	O
O	O	1055	1058	the	the	B-NP	DT	O	7	NMOD	O
T13	B-Entity	1059	1064	BamHI	BamHI	I-NP	NN	B-DNA	7	NMOD	B-DNA
T13	I-Entity	1064	1065	-	-	I-NP	HYPH	I-DNA	7	NMOD	I-DNA
T13	I-Entity	1065	1066	A	A	I-NP	NN	I-DNA	7	NMOD	I-DNA
T13	I-Entity	1067	1073	region	region	I-NP	NN	I-DNA	2	PMOD	I-DNA
O	O	1074	1076	of	of	B-PP	IN	O	7	NMOD	O
O	O	1077	1080	the	the	B-NP	DT	O	11	NMOD	O
T14	B-Entity	1081	1086	viral	viral	I-NP	JJ	B-DNA	11	NMOD	B-DNA
T14	I-Entity	1087	1093	genome	genome	I-NP	NN	I-DNA	8	PMOD	I-DNA
O	O	1094	1098	were	be	B-VP	VBD	O	0	ROOT	O
O	O	1099	1109	detectable	detectable	B-ADJP	JJ	O	12	PRD	O
O	O	1110	1112	in	in	B-PP	IN	O	13	AMOD	O
O	O	1113	1116	all	all	B-NP	DT	O	16	NMOD	O
O	O	1117	1122	cases	case	I-NP	NNS	O	14	PMOD	O
O	O	1122	1123	.	.	O	.	O	12	P	O

T7	B-Protein	1124	1129	BZLF1	BZLF1	B-NP	NN	B-RNA	2	NMOD	B-RNA
O	O	1130	1134	mRNA	mRNA	I-NP	NN	I-RNA	11	NMOD	I-RNA
O	O	1135	1138	and	and	O	CC	O	11	NMOD	O
O	O	1139	1142	the	the	B-NP	DT	O	5	NMOD	O
O	O	1143	1150	product	product	I-NP	NN	O	11	NMOD	O
O	O	1150	1151	,	,	O	,	O	11	P	O
O	O	1152	1154	an	an	B-NP	DT	O	11	NMOD	O
T15	B-Entity	1155	1164	immediate	immediate	I-NP	JJ	B-DNA	11	NMOD	B-DNA
T15	I-Entity	1164	1165	-	-	I-NP	HYPH	I-DNA	11	NMOD	I-DNA
T15	I-Entity	1165	1170	early	early	I-NP	JJ	I-DNA	11	NMOD	I-DNA
T15	I-Entity	1171	1175	gene	gene	I-NP	NN	I-DNA	16	SUB	I-DNA
O	O	1176	1179	for	for	B-PP	IN	O	11	NMOD	O
O	O	1180	1183	EBV	EBV	B-NP	NN	O	14	NMOD	O
O	O	1184	1195	replication	replication	I-NP	NN	O	12	PMOD	O
O	O	1195	1196	,	,	O	,	O	11	P	O
O	O	1197	1200	was	be	B-VP	VBD	O	0	ROOT	O
O	O	1201	1204	not	not	I-VP	RB	O	16	VMOD	O
O	O	1205	1214	expressed	express	I-VP	VBN	O	16	VC	O
O	O	1215	1217	in	in	B-PP	IN	O	18	VMOD	O
O	O	1218	1221	any	any	B-NP	DT	O	19	PMOD	O
O	O	1222	1224	of	of	B-PP	IN	O	20	NMOD	O
O	O	1225	1229	them	them	B-NP	PRP	O	21	PMOD	O
O	O	1229	1230	,	,	O	,	O	18	P	O
O	O	1231	1238	thereby	thereby	B-ADVP	RB	O	25	VMOD	O
O	O	1239	1249	suggesting	suggest	B-VP	VBG	O	18	VMOD	O
O	O	1250	1254	that	that	B-SBAR	IN	O	25	VMOD	O
O	O	1255	1258	the	the	B-NP	DT	O	29	NMOD	O
O	O	1259	1265	tumour	tumour	I-NP	NN	B-cell_type	29	NMOD	B-cell_type
O	O	1266	1271	cells	cell	I-NP	NNS	I-cell_type	30	SUB	I-cell_type
O	O	1272	1279	carried	carry	B-VP	VBD	O	26	SBAR	O
T16	B-Entity	1280	1283	EBV	EBV	B-NP	NN	B-DNA	32	NMOD	B-DNA
T16	I-Entity	1284	1291	genomes	genome	I-NP	NNS	I-DNA	30	OBJ	I-DNA
O	O	1292	1294	in	in	B-PP	IN	O	30	VMOD	O
O	O	1295	1296	a	a	B-NP	DT	O	37	NMOD	O
O	O	1297	1304	tightly	tightly	I-NP	RB	O	36	AMOD	O
O	O	1305	1311	latent	latent	I-NP	JJ	O	37	NMOD	O
O	O	1312	1316	form	form	I-NP	NN	O	33	PMOD	O
O	O	1316	1317	.	.	O	.	O	16	P	O

O	O	1318	1323	These	These	B-NP	DT	O	2	NMOD	O
O	O	1324	1332	findings	finding	I-NP	NNS	O	4	SUB	O
O	O	1333	1340	further	further	B-ADVP	RB	O	4	VMOD	O
O	O	1341	1349	extended	extend	B-VP	VBD	O	0	ROOT	O
O	O	1350	1353	our	our	B-NP	PRP$	O	7	NMOD	O
O	O	1354	1362	previous	previous	I-NP	JJ	O	7	NMOD	O
O	O	1363	1367	data	datum	I-NP	NNS	O	4	OBJ	O
O	O	1368	1377	regarding	regard	B-VP	VBG	O	7	NMOD	O
O	O	1378	1381	EBV	EBV	B-NP	NN	O	10	NMOD	O
O	O	1382	1389	latency	latency	I-NP	NN	O	8	PMOD	O
O	O	1390	1392	in	in	B-PP	IN	O	10	NMOD	O
O	O	1393	1400	gastric	gastric	B-NP	JJ	B-cell_type	14	NMOD	B-cell_type
O	O	1401	1410	carcinoma	carcinoma	I-NP	NN	I-cell_type	14	NMOD	I-cell_type
O	O	1411	1416	cells	cell	I-NP	NNS	I-cell_type	11	PMOD	I-cell_type
O	O	1417	1419	at	at	B-PP	IN	O	10	NMOD	O
O	O	1420	1423	the	the	B-NP	DT	O	18	NMOD	O
O	O	1424	1431	protein	protein	I-NP	NN	O	18	NMOD	O
O	O	1432	1437	level	level	I-NP	NN	O	15	PMOD	O
O	O	1437	1438	,	,	O	,	O	4	P	O
O	O	1439	1442	and	and	O	CC	O	4	VMOD	O
O	O	1443	1447	have	have	B-VP	VBP	O	4	VMOD	O
O	O	1448	1456	affirmed	affirm	I-VP	VBN	O	21	VC	O
O	O	1457	1461	that	that	B-SBAR	IN	O	22	VMOD	O
O	O	1462	1465	the	the	B-NP	DT	O	25	NMOD	O
O	O	1466	1475	programme	programme	I-NP	NN	O	35	SUB	O
O	O	1476	1478	of	of	B-PP	IN	O	25	NMOD	O
O	O	1479	1484	viral	viral	B-NP	JJ	O	29	NMOD	O
O	O	1485	1489	gene	gene	I-NP	NN	O	29	NMOD	O
O	O	1490	1500	expression	expression	I-NP	NN	O	26	PMOD	O
O	O	1501	1503	in	in	B-PP	IN	O	29	NMOD	O
O	O	1504	1507	the	the	B-NP	DT	O	32	NMOD	O
O	O	1508	1514	tumour	tumour	I-NP	NN	O	30	PMOD	O
O	O	1515	1519	more	more	B-ADVP	RBR	O	34	AMOD	O
O	O	1520	1527	closely	closely	I-ADVP	RB	O	35	VMOD	O
O	O	1528	1537	resembles	resemble	B-VP	VBZ	O	23	SBAR	O
O	O	1538	1539	'	'	O	``	O	37	NMOD	O
O	O	1539	1546	latency	latency	B-NP	NN	O	35	OBJ	O
O	O	1547	1548	I	I	I-NP	CD	O	37	NMOD	O
O	O	1548	1549	'	'	O	''	O	37	NMOD	O
O	O	1550	1561	represented	represent	B-VP	VBN	O	37	NMOD	O
O	O	1562	1564	by	by	B-PP	IN	O	40	VMOD	O
O	O	1565	1572	Burkitt	Burkitt	B-NP	NN	O	45	NMOD	O
O	O	1572	1573	'	'	B-NP	POS	O	45	NMOD	O
O	O	1573	1574	s	s	I-NP	NN	O	45	NMOD	O
O	O	1575	1583	lymphoma	lymphoma	I-NP	NN	O	41	PMOD	O
O	O	1584	1588	than	than	B-PP	IN	O	35	VMOD	O
O	O	1589	1590	'	'	O	``	O	48	NMOD	O
O	O	1590	1597	latency	latency	B-NP	NN	O	46	PMOD	O
O	O	1598	1600	II	II	I-NP	CD	O	48	NMOD	O
O	O	1600	1601	'	'	O	''	O	48	NMOD	O
O	O	1602	1613	represented	represent	B-VP	VBN	O	48	NMOD	O
O	O	1614	1616	by	by	B-PP	IN	O	51	VMOD	O
O	O	1617	1620	the	the	B-NP	DT	O	54	NMOD	O
O	O	1621	1629	majority	majority	I-NP	NN	O	52	PMOD	O
O	O	1630	1632	of	of	B-PP	IN	O	54	NMOD	O
O	O	1633	1647	nasopharyngeal	nasopharyngeal	B-NP	JJ	O	57	NMOD	O
O	O	1648	1658	carcinomas	carcinoma	I-NP	NNS	O	55	PMOD	O
O	O	1658	1659	.	.	O	.	O	4	P	O
